Biography

David M. Selva

David M. Selva

Diabetes and Metabolism Research Unit, Vall Hebron Institut de Recerca (VHIR). Universitat Autònoma de Barcelona and CIBERDEM (ISCIII), Spain

David Martínez Selva got Bachelor’s Degree in Biology in 1996 at the University of Barcelona. He obtained his PhD in Biochemistry and Molecular Biology at the Autonomous University of Barcelona in 2001. After PhD he accepted a postdoctoral position for 7 years in Professor Hammond laboratory first at the LRCC in the UWO, Canadaand later on at the Child and Family Research Institute (CFRI) in the University of British Columbia (UBC), Vancouver, British Columbia, Canada where he worked on the molecular mechanisms regulating hepatic SHBG production in several human SHBG transgenic mice and HepG2 cells.

Nine years ago he obtained a principal investigator position through the Miguel Servet Program in the Diabetes and Metabolism Department at the Vall d’Hebron Research Institute in Barcelona, Spain. David has two main research lines: (i) Study the molecular mechanisms regulating SHBG expression in human disease (mainly in obesity, type 2 diabetes and NAFLD). The results have been published in high impact journals: (Simo et al. Diabetes 2012, Simo et al. Mol Endocrinol 2012a, Simo et al. Mol Endocrinol 2012; Sáez et al. Mol Nutr Food Res 2014; Simo et al. Endocrinology 2015; Simo et al. Trends Endocrinol Metab. 2015). (ii) Study the role of SHBG in human disease development. The results have been published in high impact journals: (Sáez et al. Endocrinology 2015; Sáez et al. Endocrinology 2017) and allowed us to file a patent to use SHBG as a medicament to treat Obesity and NAFLD, both in Europe and USA (EP14730477.8 and US2016113852, respectively). It is also important to mention that Dr. Cristina Sáez López received the PIONER 2016 award from CERCA to the best translational thesis of 2016.